全文获取类型
收费全文 | 3372632篇 |
免费 | 239689篇 |
国内免费 | 8422篇 |
专业分类
耳鼻咽喉 | 45365篇 |
儿科学 | 110919篇 |
妇产科学 | 94118篇 |
基础医学 | 479241篇 |
口腔科学 | 93833篇 |
临床医学 | 310833篇 |
内科学 | 658414篇 |
皮肤病学 | 78954篇 |
神经病学 | 276027篇 |
特种医学 | 128682篇 |
外国民族医学 | 964篇 |
外科学 | 495991篇 |
综合类 | 69055篇 |
现状与发展 | 7篇 |
一般理论 | 1447篇 |
预防医学 | 266018篇 |
眼科学 | 75945篇 |
药学 | 246054篇 |
12篇 | |
中国医学 | 6467篇 |
肿瘤学 | 182397篇 |
出版年
2019年 | 26434篇 |
2018年 | 36776篇 |
2017年 | 28340篇 |
2016年 | 32421篇 |
2015年 | 36826篇 |
2014年 | 50718篇 |
2013年 | 76912篇 |
2012年 | 102324篇 |
2011年 | 108551篇 |
2010年 | 64983篇 |
2009年 | 62479篇 |
2008年 | 101925篇 |
2007年 | 108436篇 |
2006年 | 109651篇 |
2005年 | 105758篇 |
2004年 | 101795篇 |
2003年 | 98111篇 |
2002年 | 94815篇 |
2001年 | 156290篇 |
2000年 | 159945篇 |
1999年 | 135101篇 |
1998年 | 39152篇 |
1997年 | 34967篇 |
1996年 | 35423篇 |
1995年 | 34078篇 |
1994年 | 31418篇 |
1993年 | 29472篇 |
1992年 | 106242篇 |
1991年 | 103123篇 |
1990年 | 99910篇 |
1989年 | 96438篇 |
1988年 | 88940篇 |
1987年 | 87160篇 |
1986年 | 82168篇 |
1985年 | 78306篇 |
1984年 | 58899篇 |
1983年 | 50242篇 |
1982年 | 29963篇 |
1981年 | 26934篇 |
1979年 | 53026篇 |
1978年 | 37960篇 |
1977年 | 32208篇 |
1976年 | 29790篇 |
1975年 | 31901篇 |
1974年 | 38011篇 |
1973年 | 36665篇 |
1972年 | 34516篇 |
1971年 | 32089篇 |
1970年 | 29858篇 |
1969年 | 28501篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
62.
Interstitial cystitis/bladder pain syndrome (IC/BPS) and vulvodynia are chronic pain syndromes that appear to be intertwined from the perspectives of embryology, pathology and epidemiology. These associations may account for similar responses to various therapies. 相似文献
63.
Hsiao-Hsuan Kuo Ran Fan Nina Dvorina Andres Chiesa-Vottero William M. Baldwin III 《Journal of the American Society of Nephrology : JASN》2015,26(4):855-863
Antibody-mediated rejection is a major complication in renal transplantation. The pathologic manifestations of acute antibody-mediated rejection that has progressed to functional impairment of a renal transplant have been defined in clinical biopsy specimens. However, the initial stages of the process are difficult to resolve with the unavoidable variables of clinical studies. We devised a model of renal transplantation to elucidate the initial stages of humoral rejection. Kidneys were orthotopically allografted to immunodeficient mice. After perioperative inflammation subsided, donor-specific alloantibodies were passively transferred to the recipient. Within 1 hour after a single transfer of antibodies, C4d was deposited diffusely on capillaries, and von Willebrand factor released from endothelial cells coated intravascular platelet aggregates. Platelet-transported inflammatory mediators platelet factor 4 and serotonin accumulated in the graft at 100- to 1000-fold higher concentrations compared with other platelet-transported chemokines. Activated platelets that expressed P-selectin attached to vascular endothelium and macrophages. These intragraft inflammatory changes were accompanied by evidence of acute endothelial injury. Repeated transfers of alloantibodies over 1 week sustained high levels of platelet factor 4 and serotonin. Platelet depletion decreased platelet mediators and altered the accumulation of macrophages. These data indicate that platelets augment early inflammation in response to donor-specific antibodies and that platelet-derived mediators may be markers of evolving alloantibody responses. 相似文献
64.
65.
66.
67.
Discordant Electrocardiogram Left Ventricular Wall Thickness and Strain Findings in Influenza Myocarditis
下载免费PDF全文
![点击此处可从《Echocardiography (Mount Kisco, N.Y.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Nael Hawwa M.D. Zoran B. Popovic M.D. Ph.D. Hussain A. Isma'eel M.D. 《Echocardiography (Mount Kisco, N.Y.)》2015,32(12):1880-1884
A 42‐year‐old man presented with a viral prodrome and tested positive for influenza A. He rapidly deteriorated developing cardiogenic shock, rhabdomyolysis, and acute kidney injury. Patient improved 1 week later with supportive measures including vasopressors, inotropes, and an intraaortic balloon pump. We report this case as it highlights the discordance between echocardiographic ventricular wall thickening as a result of myocardial edema, and electrocardiographic findings at presentation, with a reversal in findings at time of resolution. Additionally, there was some suggestion of a regional pattern to the reduced longitudinal strain. 相似文献
68.
69.
70.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献